Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Canaccord Genuity 46th Annual Growth Conference 2026
17 slides from Angiodynamics's conference presentation, Aug 11, 2026
Slide 1: Canaccord Genuity 46th Annual Growth Conference
Canaccord Genuity 46th Annual Growth Conference August 11, 2026 Jim Clemmer, President & CEO Stephen Trowbridge, Executive Vice President & CFO
Slide 2: Forward looking statements
Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: AngioDynamics
AngioDynamics Our proven success positions us for sustained growth and profitability in key markets. 2020 - Today Today & Beyond Drove Performance and Built a More Dynamic Growth Positioned for Sustained Profitable Growth Focused Company Accelerating Commercial Investment Sharpened Portfolio Focus •
Slide 4: Unrivaled Innovation
Unrivaled Innovation Our synergistic portfolio is focused on providing comprehensive solutions to help treat patients within two of the largest global healthcare markets Cardiovascular Disease Cancer ARTERIAL VENOUS Med Tech Peripheral Artery Disease Venous Thromboembolism Prostate Care (PAD) (VTE)
Slide 5: Demonstrated Med Tech Growth Execution
Demonstrated Med Tech Growth Execution Pro Forma Fiscal Year Net Sales ($M) $320 $293 $271 $257 Med Tech $235 $150 ~47% of $206 $127 +18.4% $186 $96 $106 Total Med Tech $79 $56 ~22% of Total $41 $157 $161 $165 $166 $170 $145 $151 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 A Med Device Med Tech 5
Slide 6: Cardiovascular Arterial
Cardiovascular Arterial Since its launch in September 2020, Auryon has been used in nearly 180,000 procedures and surpassed $255M in cumulative sales MARKET DYNAMICS Peripheral Artery Disease (PAD) • Hospital market growth fuels ASP stability Addressable • New and expanded reimbursement coverage sol
Slide 7: Cardiovascular Venous
Cardiovascular Venous Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity MARKET DYNAMICS PE PE + DVT = Venous Thromboembolism (VTE) $2.4B • Mechanical Thrombectomy for PE is estimated to have penetrated ~20% of the TAM • Mechanical Thrombectomy for
Slide 8: Mechanical Thrombectomy
Mechanical Thrombectomy Proprietary funnel cannula technology with the ability to have aspiration and simultaneous reinfusion with AngioVac or off-circuit manual aspiration control with AlphaVac AlphaVac Indicated for Treatment of Pulmonary Embolism Aspiration & Simultaneous Reinfusion • Minimally i
Slide 9: APEX – AV Pivotal Study
APEX – AV Pivotal Study AlphaVac received FDA clearance for PE following APEX-AV study demonstrating efficacy and significantly improved reduction in clot burden vs. competitive technologies Number of Sites 25 US Sites Number of Patients 122 Timeline Oct. 2022 – Dec 2023 Significant reduction in the
Slide 10: Prostate Cancer
Prostate Cancer Backed by real world evidence and compelling clinical data, NanoKnife is a one-of-a-kind technology poised to change the standard of care of men with prostate cancer MARKET DYNAMICS Prostate Cancer is Prevalent, On the Rise & Debilitating Intermediate • The most diagnosed male cancer
Slide 11: Irreversible Electroporation (IRE)
Irreversible Electroporation (IRE) Preserves the underlying structure of tissue giving physicians a more precise tool Only IRE device FDA cleared for prostate tissue DECELLULARIZATION Destroys targeted tissue with precise Efficiently treats all segments of the prostate treatment margins. Easy clinic
Slide 12: PRESERVE Pivotal Study
PRESERVE Pivotal Study NanoKnife safely & effectively treats prostate tumors while avoiding the high incidence of erectile dysfunction and incontinence associated with radical surgery and radiation Number of Sites 17 US Sites Number of Patients 121 Primary Endpoint Follow Up 12 Months Efficacy Safet
Slide 13: FY 2026 Key Takeaways
FY 2026 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. YoY Revenue Total Med Tech Med Device Growth* +9.4% +18.4% +2.5% Med Tech YoY Auryon Mech Thrombectomy NanoKnife Probes Revenue Growth* +17.7% 13.4% +28.7% • Net sales of $32
Slide 14: Fiscal Year 2027 Guidance
Fiscal Year 2027 Guidance supported by balance sheet strength FY 2026 Net Sales ($M) FY 2027 Financial Guidance* $336 - $341 Current $320 Metric Guidance Net Sales $336.0M - $341.0M +12 - 15% Med Tech Med Tech Net Sales Growth +12% - 15% Med Device Net Sales Growth Flat Gross Margin 54% – 55% Flat A
Slide 15: Strong Product & Clinical Pipeline
Strong Product & Clinical Pipeline Leveraging our leading platforms to fuel innovation, market expansion, and long-term shareholder value in key growth markets FY26 & Earlier FY27 – FY31 Platform $7.2B US TAM $10.9B US TAM Peripheral Artery Disease: $800M US TAM IVL Indication DVT: $2.8B US TAM Coro
Slide 16: Ongoing Clinical Initiatives to Support Growth
Ongoing Clinical Initiatives to Support Growth Initiative Purpose Overview A randomized controlled trial of the Auryon Atherectomy System + Increased utilization within the balloon angioplasty vs. standard angioplasty alone for below-the-knee AMBITION BTK below the knee critical limb lesions with cr
Slide 17: AngioDynamics Investment Summary
AngioDynamics Investment Summary Attractive MedTech Platforms in High-Value Markets Our MedTech segment operates in large, growing clinical markets, supported by differentiated technologies and proven clinical outcomes. Demonstrated Execution and Portfolio Discipline We have a strong track record of
AngioDynamics — Canaccord Genuity 46th Annual Growth Conference 2026 on 6ix